InvestorLens

LLY — ELI LILLY & CO

Health Care · Drug Manufacturers

Sign in to save6 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying LLY?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
60
Institutional Conviction
Mixed · 3 buying vs 2 selling last quarter
48
Macro Tailwind
Macro conditions are mixed for this sector
53
Congressional Activity
3 congressional purchases, 2 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 5 tracked investors who changed their LLY position last quarter, 3 bought and 2 sold (60% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime). 3 congressional purchases, 2 sales disclosed in the last 6 months.

Supporting evidence
  • +3 tracked investors added or increased positions last quarter (Stanley Druckenmiller, Cathie Wood, Ray Dalio)
  • +6 tracked investors reported holding LLY at their latest filing
  • +3 congressional purchases disclosed in the last 6 months
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (2 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About ELI LILLY & CO (LLY)

ELI LILLY & CO (LLY) appears in the most recent 13F filings of 6 tracked institutional investors. ELI LILLY & CO is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $6.2B. Across recent filings, tracked investors recorded 15 new positions, 18 increased, 22 reduced, and 9 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in LLY

52
/100
Mixed Activity
Added / Increased33
Reduced22
Exited9
BearishBullish
Crowded Trade Score™

How many top investors track LLY

40
/100
Moderate Interest
6investors

Several tracked investors have exposure.

UndiscoveredCrowded
151015+

LLY Ownership Composition

How ELI LILLY & CO is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
96% of tracked value
Institutions
6
tracked investors
Total Reported
$7.6B
combined 13F value
Types3
  • Multi-Strategy / Quant95.8%
  • Macro2.9%
  • Growth & Innovation1.2%
Multi-Strategy / Quant(3)
95.8%
Macro(2)
2.9%
Growth & Innovation(1)
1.2%

Tracked investors currently reporting LLY

5 tracked investors have since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    5.2M
    Value
    $6.2B
    % Portfolio
    0.71%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    779.9K
    Value
    $935.4M
    % Portfolio
    0.34%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    87K
    Value
    $104.4M
    % Portfolio
    0.43%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    98.7K
    Value
    $118.4M
    % Portfolio
    0.16%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    76.9K
    Value
    $92.2M
    % Portfolio
    0.10%
  • Cathie WoodJun 30, 2026
    ARK Investment Management
    Shares
    77.3K
    Value
    $92.7M
    % Portfolio
    0.60%

Previously held LLY

These investors reported LLY in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Chase ColemanTiger Global Management1.5M$1.2BJun 30, 2025
Steve MandelLone Pine Capital551.8K$455.8MMar 31, 2025
Andreas HalvorsenViking Global Investors416.9K$325MJun 30, 2025
Stanley DruckenmillerDuquesne Family Office402.6K$234.7MDec 31, 2023
Philippe LaffontCoatue Management117.4K$91.5MJun 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold LLY?
6 tracked institutional investors disclosed a position in LLY (ELI LILLY & CO) in their most recent 13F filing.
Who is the largest institutional holder of LLY?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in LLY, valued at $6.2B.
Did institutional ownership of LLY increase or decrease?
Across recent 13F filings, tracked investors recorded 15 new positions, 18 increased, 22 reduced, and 9 fully exited LLY.
What sector is LLY in?
ELI LILLY & CO is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this LLY ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
LLY (ELI LILLY & CO) — Institutional Holders & 13F History — InvestorLens